Phase I-II diaziquone chemotherapy in brain tumors.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; C029108:diaziquone